Cargando…
Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9
Microbiome composition can impact disease courses and also immunotherapy outcomes in solid tumours. It is still unclear how the microbiome might impact treatments in oncology, but also how modulation via antibiotics might interfere. Elegant work now identified interleukin-9 and dysbiosis as relevant...
Autor principal: | Halama, Niels |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652919/ https://www.ncbi.nlm.nih.gov/pubmed/32843683 http://dx.doi.org/10.1038/s41416-020-01030-0 |
Ejemplares similares
-
The next age of immunotherapy: optimisation, stratification and therapeutic synergies
por: Halama, Niels
Publicado: (2018) -
Machine learning for tissue diagnostics in oncology: brave new world
por: Halama, Niels
Publicado: (2019) -
Insights into the molecular mechanisms and therapeutic implications of interleukin-6 for inflammatory bowel disease
por: Tie, Yizhe, et al.
Publicado: (2023) -
Analyzing the intestinal microbiome in inflammatory bowel disease: From RNA to multiomics
por: Lett, Bron, et al.
Publicado: (2020) -
Neonatal Microbiome, Intestinal Inflammation, and Necrotizing Enterocolitis
por: Burge, Kathryn Y., et al.
Publicado: (2022)